Title: BIOCOMPATIBLE GRAPHENE QUANTUM DOTS FOR DRUG DELIVERY AND BIOIMAGING APPLICATIONS

SINGH; National Chemical Laborat Dr. Homi Bhabha Road; National Chemical Laboratory

Patent

Atlas literature

Patent

US 9,642,815

Title: BIOCOMPATIBLE GRAPHENE QUANTUM DOTS FOR DRUG DELIVERY AND BIOIMAGING APPLICATIONS

SINGH, Neetu, CHAND, Anil

COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH·7 May 2015·US

Drawings

Patent drawings and their descriptions. Click a drawing to enlarge it.

FIG. 1

FIG. 1 1 A shows FTIR spectra for P-GQD, C-GQD and H-GQD. PEG and GQD signature peaks are shown by red and black arrows respectively.

FIG. 2

FIG. 2 depicts the photoluminescence spectra and photoluminescence excitation spectra of crude-GQD, hydro-GQD and PEG-GQD. [0027]

FIG. 3

FIG. 3 depicts FTIR (Fourier Transform infrared spectroscopy) spectra exhibiting pegylation of GQD compared to crude GQD and hydrothermal GQD, the PEG …

FIG. 4

FIG. 4B depict Transmission Electron microscopy images wherein

FIG. 5

FIG. 5B depict the % cell viability of HeLa cells by normalized MTT (3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay for Crude, Hydro and …

FIG. 6

FIG. 6 depicts ﬂuorescence microscopy images of HeLa cells incubated with GQDs imaged via DAPI (4',6-diamidino-2-phenylindole) ﬁlters. Scale bars are 50 pm. …

FIG. 7

FIG. 7A shows ROS production in solution containing samples with 20 p M H₂₀₂ at 0 and 90 m in.

FIG. 8

FIG. 8A shows Absorbance spectra and

FIG. 9

FIG. 9C shows 4 mg/mL (SEM). [0034]

FIG. 10

FIG. 10A through FIG. IO C depict: Optical and size characterization for unmodiﬁed GQDs (C-GQDs), Single PEG shell coated GQDs (S-GQDs) and matrix embedded …

FIG. 11

FIG. 12

FIG. 12: C i s XPS spectra of C-GQD, H-GQD and P-GQD indicating surface changes during the PEGylation process. The reduction of oxygenated functional groups in …

FIG. 13

FIG. 13D depict: TEM images of

FIG. 14

FIG. 14A shows Absorbance spectra of C- GQD, H-GQD and P-GQD with inset showing image of the GQD solution in water under white light and UV. The small peak at …

FIG. 15

FIG. 15A shows Schematic representation of protein interaction study of GQDs with BSA. Polyacrylamide gel electrophoresis (PAGE) showing quantity of BSA in

FIG. 16

FIG. 16: Hela cell viability for C-GQD, S-GQD, H-GQD and P-GQD assessed by MTT assay. [0041]

FIG. 17

performance graph

FIG. 17B: Bar graph showing ﬂuorescence values due to ROS production at 0 and 90 minutes for GQD + 10 pM H 2 0 2, clearly indicating the maximum increase in …

FIG. 18

FIG. 18A: Fluorescence intensities for cell free ROS assay after 0 and 75 minutes of incubation of GQDs with 20 p M H202. After 75 minutes, P-GQDs showed very …

FIG. 19

FIG. 19B depict: Intracellular ROS generation in HeLa cells incubated with GQDs, visualized by ﬂuorescence microscopy (Scale bar = 50 pm, Magniﬁcation 40x). …

FIG. 20

FIG. 20: Fluorescence microscopy images showing delivery of doxorubicin with P-GQD- Dox, H-GQD-Dox and C-GQD-Dox. Red: Dox, Blue: GQDs. (Scale bar = 20 p m, …

Claims

Claims define the patent's legal scope. Independent claims stand alone; dependent claims (nested) narrow them. Click a claim to expand its dependents.

1 independent · 3 dependent

1
Independentmulti-walled carbon nanotubespolyethylene glycolPEG-GQD nanoparticles
Biocompatible composition with reduced cytotoxicity comprising graphene quantum dots (GQDs) with a particle size ranging from 5-10 nm embedded in polyethylene glycol (PEG) matrix with a particle size ranging from 80-100 nm, for drug delivery and biomedical applications.
1. 2
  Dependent← claim 1PEG-GQD nanoparticles
  The biocompatible composition as claimed in claim 1, wherein the composition of PEG-GQD at a concentrations of about 8 mg/mL shows upto 50% cell viability when tested on HeLa cell lines.
2. 3
  Dependent← claim 1multi-walled carbon nanotubespolyethylene glycolPEG-GQD nanoparticles
  A process for preparation of biocompatible composition as claimed in claim 1 comprising the steps of: i. electrochemical etching of multi walled carbon nanotubes at temperature in the range of 25 ° -28 ° C for period in the range of 11 to 12 hrs to provide graphene quantum dots of size 5-10 nm; ii. mixing graphene quantum dots as obtained in step (i) with polyethylene glycol followed by sonicating at temperature in the range of 20 to 35 ° C for period in the range of 25 to 30 minutes to obtain a solution; iii. autoclaving the solution as obtained in step (ii) at temperature in the range of 140 ° -180 ° C for 23 to 24 hrs and; iv. cooling at room temperature in the range of 20 to 35 ° C followed by dialyzing to obtain biocompatible composition.

Materials

Materials described outside the worked examples.

multi-walled carbon nanotubes

Precursor

polyethylene glycol

Matrix Material

PEG-GQD nanoparticles

Process steps

Additional fabrication and treatment steps described in the patent.

Electrochemical Etching

Step 1

Temperature

25, 28°C

Duration

660, 720 min

Process details

product size:5-10 nm GQDs

starting material:

Characterization

Measurements and analyses referenced in the patent, with their drawing references.

photoluminescence

Photoluminescence

FIG. 1 1 A shows FTIR spectra for P-GQD, C-GQD and H-GQD. PEG and GQD signature peaks are shown by red and black arrows respectively.

Figure references

FIG. 1

optical absorption

Reported properties

Performance values and ranges asserted in the specification or claims.

Property	Value	Material
Particle Size	5–10 nm	graphene quantum dots
Particle Size	80–100 nm

Why these are connected

Related documents with shared materials, methods, properties, or citations.

Title: BIOCOMPATIBLE GRAPHENE QUANTUM DOTS FOR DRUG DELIVERY AND BIOIMAGING APPLICATIONS | Matter42 Literature